Introduction
============

The global burden of influenza in children is high, and infants and toddlers aged \<3 y are particularly vulnerable to influenza infection and severe respiratory complications; influenza-related childhood mortality in the US is reported to be highest in children aged \<6 mo, followed by those aged 6 to 23 mo.[@R1]^-^[@R4] Inactivated trivalent influenza vaccines (TIVs) are indicated for the active immunization of children from 6 mo of age, but in vaccine-naïve children less than 9 y of age, 2 doses given at least 28 d apart are needed to provide adequate immunogenicity.[@R5]

The oil-in-water adjuvants AS03 and MF59 have been shown to enhance the immunogenicity of influenza vaccines in children,[@R6]^-^[@R9] and in children aged 6 to \<36 mo, the efficacy of 2 doses of MF59-adjuvanted TIV against PCR-confirmed seasonal influenza was 79% compared with 40% for conventional TIV.[@R7] Experience with AS03-adjuvanted vaccines against pandemic influenza show that this Adjuvant System containing α-tocopherol and squalene in an o/w emulsion improves immunogenicity compared with non-adjuvanted vaccine in various populations.[@R10]^,^[@R11]

An AS03-adjuvanted vaccine against A(H1N1)pdm09 was recommended for use in children, with the pediatric formulation containing a 1.9 μg dose of A(H1N1)pdm09 hemagglutinin antigen (HA) and adjuvanted with AS03~B~ containing half the amount of tocopherol as the adult AS03~A~ formulation. During the pandemic vaccination campaign, 2 doses of this vaccine given 21 d apart was shown to be more immunogenic than non-adjuvanted whole virion vaccine in children aged 6 mo to 12 y, and seroconversion rates were \>90% in children aged 6 mo to 3 y.[@R9] However, an increase in injection site and general adverse events (AEs) after the second compared with the first dose of AS03~B~-adjuvanted A(H1N1)pdm09 vaccine was observed, including an increase in the rate of fever (≥38 °C).[@R12]^,^[@R13] This experience highlights the need to empirically establish an antigen and adjuvant formulation that balances immunogenicity and reactogenicity for use in young children.

In this phase 1, open-label study of influenza vaccine-naïve children aged 6 to 35 mo, we assessed the reactogenicity, safety, and immunogenicity of a seasonal TIV containing 7.5 µg HA of each strain, adjuvanted with various doses of AS03, followed by a 6-mo booster dose of conventional TIV (non-adjuvanted containing 15 µg HA of each strain). The rationale for assessing different doses of AS03 was to ascertain if lowering the dose could reduce vaccine reactogenicity without compromising immunogenicity, and the rationale for the booster dose was to assess the quality of the immunological memory created by primary vaccination.

Results
=======

Twenty children received 2 doses of TIV-AS03~D~ and 20 received 1 dose of TIV-AS03~C~. The mean age was 23.2 mo in the TIV-AS03~D~ group and 18.6 mo in the TIV-AS03~C~ group ([Table 1](#T1){ref-type="table"}). There were no study discontinuations for an adverse event/serious adverse event (AE/SAE). The first child was enrolled on 30 March 2010 and the last study visit was on 15 June 2010.

###### **Table 1.** Demographic details in the total vaccinated cohort

  --------------------------------------------------------------------------------------------------
                                                                       TIV-AS03~D~\   TIV-AS03~C~\
                                                                       n = 20         n = 20
  ---------------------------- --------------------------------------- -------------- --------------
  Age, months                  Mean                                    23.2           18.6

  SD                           9.82                                    7.46           

  Median                       27.0                                    20.5           

  Minimum                      8                                       8              

  Maximum                      35                                      35             

  Sex, n (%)                   Female                                  11 (55.0)      7 (35.0)

  Male                         9 (45.0)                                13 (65.0)      

  Geographic ancestry, n (%)   White--Caucasian or European heritage   20 (100)       20 (100)
  --------------------------------------------------------------------------------------------------

TIV, trivalent inactivated influenza vaccine; AS03, oil-in-water emulsion Adjuvant System containing 1.48 mg (AS03~D~) or 2.97 mg (AS03~C~) of α-tocopherol; SD, standard deviation.

From the 40 children in the total vaccinated cohort, the per-protocol immunogenicity cohort included 14 and 17 children in the TIV-AS03~D~ and TIV-AS03~C~ groups, respectively; in the TIV-AS03~D~ group, 5 children were excluded due to receiving a forbidden vaccine, and 1 did not comply with the blood sampling schedule; in the TIV-AS03~C~ group, 3 children were excluded, including 1 each for receiving a forbidden vaccine, non-compliance with the blood sampling schedule, and because essential serology data were missing.

Reactogenicity
--------------

During the 7-d post-vaccination period, fever \>38.0 °C was reported in 5 (25.0%; 95% confidence interval \[CI\]: 8.7, 49.1) and in 7 (35.0%; 95% CI: 15.4, 59.2) children after the first and second TIV-AS03~D~ vaccination, respectively, including 3 (15.0%; 95% CI: 3.2, 37.9) and 5 (25.0%; 95% CI: 8.7, 49.1) reports, respectively, that were considered to be related to vaccination. After vaccination with TIV-AS03~C~, there were 7 (35.0%; 95% CI: 15.4, 59.2) reports of fever \>38.0 °C including 5 (25.0%; 95% CI: 8.7, 49.1) that were considered to be related to vaccination. The incidence of fever \>38.0 °C during 3 d after the first dose of TIV-AS03~C~ fulfilled the pre-defined holding-rule.

All fever (≥37.5 °C) was reported in 7 (35.0%; 95% CI: 15.4, 59.2) and 9 (45.0%; 95% CI: 23.1, 68.5) children, after the first and second TIV-AS03~D~ vaccination, respectively, and in 12 (60.0%; 95% CI: 36.1, 80.9) children after the TIV-AS03~C~ vaccination ([Table 2](#T2){ref-type="table"}). The majority of fever episodes lasted for up to 1 d: TIV-AS03~D~ 4 and 6 episodes, post dose-1 and dose-2, respectively; TIV-AS03~C~, 11 episodes. There were 2 episodes of fever (any grade) that lasted for 2 d after the second dose of TIV-AS03~D~, and 5 episodes that lasted ≥3 d: TIV-AS03~D~ 3 and 1 episodes, post dose-1 and dose-2, respectively; TIV-AS03~C~, 1 episode.

###### **Table 2.** Incidence of solicited general events during the 7-d post-vaccination period

  --------------------------------------------------------------------------------------------------
                               TIV-AS03~D~\           TIV-AS03~C~\           
                               n = 20                 n = 20                 
  ---------------------------- ---------------------- ---------------------- -----------------------
  Drowsiness                   All                    4; 20.0 (5.7, 43.7)    7; 35.0 (15.4, 59.2)

  Grade 3                      0; 0.0 (0.0, 16.8)     1; 5.0 (0.1, 24.9)     

  Irritability                 All                    4; 20.0 (5.7, 43.7)    9; 45.0 (23.1, 68.5)

  Grade 3                      1; 5.0 (0.1, 24.9)     1; 5.0 (0.1, 24.9)     

  Loss of appetite             All                    9; 45.0 (23.1, 68.5)   5; 25.0 (8.7, 49.1)

  Grade 3                      0; 0.0 (0.0, 16.8)     1; 5.0 (0.1, 24.9)     

  Vomiting                     All                    5; 25.0 (8.7, 49.1)    4; 20.0 (5.7, 43.7)

  Grade 3                      2; 10.0 (1.2, 31.7)    1; 5.0 (0.1, 24.9)     

  Temperature (axillary, °C)   All (≥37.5)            7; 35.0 (15.4, 59.2)   12; 60.0 (36.1, 80.9)

  \>38.0                       5; 25.0 (8.7, 49.1)    7; 35.0 (15.4, 59.2)   

  \>39.0                       0; 0.0 (0.0, 16.8)     1; 5.0 (0.1, 24.9)     

  \>40.0                       0; 0.0 (0.0, 16.8)     1; 5.0 (0.1, 24.9)     

  **Dose 2**                                                                 

  Drowsiness                   All                    4; 20.0 (5.7, 43.7)     

  Grade 3                      0; 0.0 (0.0, 16.8)                            

  Irritability                 All                    4; 20.0 (5.7, 43.7)     

  Grade 3                      0; 0.0 (0.0, 16.8)                            

  Loss of appetite             All                    5; 25.0 (8.7, 49.1)     

  Grade 3                      0; 0.0 (0.0, 16.8)                            

  Vomiting                     All                    3; 15.0 (3.2, 37.9)     

  Grade 3                      0; 0.0 (0.0, 16.8)                            

  Temperature (axillary, °C)   All (≥ 37.5)           9; 45.0 (23.1, 68.5)    

  \>38.0                       7; 35.0 (15.4, 59.2)                          

  \>39.0                       2; 10.0 (1.2, 31.7)                           

  \>40.0                       0; 0.0 (0.0, 16.8)                            
  --------------------------------------------------------------------------------------------------

TIV, trivalent inactivated influenza vaccine; AS03, oil-in-water emulsion Adjuvant System containing 1.4mg (AS03~D~) or 2.97 mg (AS03~C~) of α-tocopherol; SD: standard deviation; CI, confidence interval.

The most frequent solicited general events (any grade) after the first dose of TIV-AS03~D~ were loss of appetite (9; 45.0%; 95% CI: 23.1, 68.5) and any grade fever (7; 35.0%; 95% CI: 15.4, 59.2), and after the second dose this was any grade fever (9; 45.0%; 95% CI: 23.1, 68.5) ([Table 2](#T2){ref-type="table"}). The most frequent general events (any grade) after TIV-AS03~C~ were fever (12; 60.0%; 95% CI: 36.1, 80.9) and irritability (9; 45.0%; 95% CI: 23.1, 68.5). The incidence of grade 3 general events was low ([Table 2](#T2){ref-type="table"}).

Injection site pain was the most frequent solicited injection site event in both vaccine groups ([Fig. 1](#F1){ref-type="fig"}). Pain (any grade) was reported in 6 (30.0%; 95% CI: 11.9, 54.3) children in each vaccine group after the first vaccination, and in 7 (35.0%; 95% CI: 15.4, 59.2) children after the second TIV-AS03~D~ vaccination. There were no reports of grade 3 pain. The mean duration of pain overall was between 1 and 3.5 d. There were 2 (10.0%; 95% CI: 1.2, 31.7) reports of redness in each vaccine group after the first vaccination, and 6 (30.0%; 95% CI: 11.9, 54.3) reports after the second TIV-AS03~D~ vaccination, of which 5 (25.0%; 95% CI: 8.7, 49.1) were grade 2.

![**Figure 1.** Incidence of solicited injection site events during the 7-d post-vaccination period. TIV, inactivated trivalent influenza vaccine;AS03, oil-in-water emulsion Adjuvant System containing 1.48mg (AS03~D~) or 2.97 mg (AS03~C~) of α-tocopherol;SD, standard deviation;CI, confidence interval; Pain: Grade 1, minor reaction on touch; Grade 2, cries on touch; Grade 3, cries when limb is moved/spontaneously painful ;Redness/swelling: Grade 1, \>0 to ≤20 mm; Grade 2, \>20 to ≤50 mm; Grade 3, \>50 mm.](hvi-10-1959-g1){#F1}

Reactogenicity during the 7-d post-vaccination period after the TIV booster dose is shown in [Table 3](#T3){ref-type="table"}. The rate of all fever (≥37.5 °C) after the TIV booster was the same in groups primed with TIV-AS03~D~ (n = 4; 20.0%; 95% CI: 5.7, 43.7) and with TIV-AS03~C~ (n = 4; 21.1%; 95% CI: 6.1, 45.6). Most of the children (6/8) developed fever on the day of vaccination or the next day with fever of maximum 38.0 °C. For the 2 others, 1 had an episode of fever starting at day 3 with a maximum of 38.5 °C in the TIV-AS03~D~ group and 1 an event starting at day 5 with a maximum \>40 °C and was considered not related to vaccination with a diagnosed tonsillitis in the TIV-AS03~C~ group.

###### **Table 3.** Incidence of solicited injection site and general events during the 7-d post-vaccination period after vaccination with TIV booster

  -----------------------------------------------------------------------------------------
                        TIV-AS03~D~\         TIV-AS03~C~\            
                        n = 20               n = 19                  
  --------------------- -------------------- ----------------------- ----------------------
  Pain                    All                10; 50.0 (27.2, 72.8)   4; 21.1 (6.1, 45.6)

  Grade 3               0; 0.0 (0.0, 16.8)   0; 0.0 (0.0, 17.6)      

  Redness               All                  8; 40.0 (19.1, 63.9)    5; 26.3 (9.1, 51.2)

  Grade 3               1; 5.0 (0.1, 24.9)   0; 0.0 (0.0, 17.6)      

  Swelling              All                  5; 25.0 (8.7, 49.1)     3; 15.8 (3.4, 39.6)

  Grade 3               1; 5.0 (0.1, 24.9)   0; 0.0 (0.0, 17.6)      

  Drowsiness            All                    5; 25.0 (8.7, 49.1)   3; 15.8 (3.4, 39.6)

  Grade 3               1; 5.0 (0.1, 24.9)   0; 0.0 (0.0, 17.6)      

  Irritability          All                  6; 30.0 (11.9, 54.3)    6; 31.6 (12.6, 56.6)

  Grade 3               0; 0.0 (0.0, 16.8)   0; 0.0 (0.0, 17.6)      

  Loss of appetite      All                  4; 20.0 (5.7, 43.7)     2; 10.5 (1.3, 33.1)

  Grade 3               0; 0.0 (0.0, 16.8)   0; 0.0 (0.0, 17.6)      

  Vomiting              All                  3; 15.0 (3.2, 37.9)     2; 10.5 (1.3, 33.1)

  Grade 3               0; 0.0 (0.0, 16.8)   0; 0.0 (0.0, 17.6)      

  Fever\                All (≥37.5)          4; 20.0 (5.7, 43.7)     4; 21.1 (6.1, 45.6)
  (axillary temp, °C)                                                

  \>38.0                1; 5.0 (0.1, 24.9)   3; 15.8 (3.4, 39.6)     

  \>39.0                0; 0.0 (0.0, 16.8)   1; 5.3 (0.1, 26.0)      

  \>40.0                0; 0.0 (0.0, 16.8)   1; 5.3 (0.1, 26.0)      
  -----------------------------------------------------------------------------------------

TIV, trivalent inactivated influenza vaccine; AS03, oil-in-water emulsion Adjuvant System containing 1.48 mg (AS03~D~) or 2.97 mg (AS03~C~) α-tocopherol; CI, confidence interval

Safety
------

From day 0 to day 42, at least 1 unsolicited AE(s) classified by MedDRA (Medical Dictionary for Regulatory Activities) Preferred Term was reported by 14 (70.0%) children with TIV-AS03~D~ (2 doses) and 12 (60.0%) children with TIV-AS03~C~ (1 dose) ([Table S1](#SUP2){ref-type="supplementary-material"}). The most frequent unsolicited AEs after 2 doses of TIV-AS03~D~ were upper respiratory tract infection and pyrexia with 5 reports each (25.0% each), and after 1 dose of TIV-AS03~C~ there were 7 (35.0%) reports of upper respiratory tract infection ([Table S1](#SUP2){ref-type="supplementary-material"}). From day 0 to month 6 + 21 d, 18 (90.0%) children in the TIV-AS03~D~ group and all children in the TIV-AS03~C~ group experienced a medically-attended adverse event (MAE); in both groups, MAEs were most frequently upper respiratory tract infection ([Table S2](#SUP2){ref-type="supplementary-material"}).

There were 3 SAEs reported from day 0 to month 6 + 21 d, all of which were in the TIV-AS03~C~ group, including one case each of tonsillitis, vasovagal syncope, and bronchopneumonia. There were no potential immune-mediated diseases (pIMDs). None of the unsolicited AEs/SAEs were considered to be associated with the study vaccines. No child was withdrawn from the study due to an AE/SAE.

Immunogenicity
--------------

Both vaccines elicited strong immune responses. The hemagglutination-inhibition (HI) Geometric Mean Titer (GMTs) at day 42 after 2 doses of TIV-AS03~D~ were 905.2 (A(H1N1)pdm09), 722.5 (A/H3N2), and 460.5 (B-strain), and after 1 dose of TIV-AS03~C~ were 617.1 (A(H1N1)pdm09), 160.0 (A/H3N2) and 63.1 (B-strain). HI seroprotection rates (SPRs; proportion with titer of ≥1:40), seroconvertion rates (SCRs; proportion of seronegative at baseline with post-vaccination titer of ≥1:40, or pre-vaccination titer of ≥1:10 and ≥4-fold increase post-vaccination), and Geometric Mean Fold Rises (GMFRs; fold increase in GMT for post- vs. pre-vaccination) exceeded adult licensure criteria for influenza vaccines against all vaccine strains at day 42 ([Fig. 2](#F2){ref-type="fig"}). Apart from the B-strain in the TIV-AS03~C~ group, the SPRs and SCRs were 100% for all vaccine strains ([Fig. 2](#F2){ref-type="fig"}). Antibody titers 21 d after the second dose of TIV-AS03~D~ were stronger than antibody titers 42 d after 1 dose of TIV-AS03~C~.

![**Figure 2.** Hemagglutination-inhibition antibody titers at day 0 and day 42; Geometric mean titer (**A**); Seroprotection rate (**B**); Seroconversion rate (**C**); Geometric mean fold rise (**D**): children received 2 doses of TIV-AS03~D~ or 1 dose of TIV-AS03~C~. TIV, inactivated trivalent influenza vaccine; AS03, oil-in-water emulsion Adjuvant System containing 1.48 mg (AS03~D~) or 2.97 mg (AS03~C~) α-tocopherol; CI, Confidence Interval.](hvi-10-1959-g2){#F2}

At month 6, all children in the TIV-AS03~D~ group remained seropositive (≥ 1:10) for the primary vaccine strains, and the month 6 seropositivity rates in the TIV-AS03~C~ group ranged from 57.9% to 89.5% ([Table 4](#T4){ref-type="table"}). At month 6 + 21 d, SPRs against the TIV booster strains were 100% in both vaccine groups. HI SPRs, SCRs, and GMFRs exceeded adult influenza vaccine licensure criteria for the TIV booster vaccine strains that were homologous (A(H1N1)pdm09 and B-strain) and heterologous (A/H3N2) to the primary vaccine strains ([Table 5](#T5){ref-type="table"}).

###### **Table 4.** Hemagglutination-inhibition based seropositivity rates, SPRs, and GMTs against the AS03-TIV vaccine strains at day 42 and month 6 after 2 doses of TIV-AS03~D~ or 1 dose of TIV-AS03~C~ and 21 d after the TIV booster dose (month 6 + 21 d)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
                  Titer ≥ 1:10   Titer ≥ 1:40            GMT                                                                                       
  --------------- -------------- ----------------------- ----------------------- ----------------------- ---------------------- ------------------ ---------------
  A(H1N1)pdm09    TIV-AS03~D~    day 0                   20                      6; 30.0 (11.9, 54.3)    6; 30.0 (11.9, 54.3)   13.7 (6.5, 28.9)   \<10.0, 320.0

  day 42          20             20; 100 (83.2, 100)     20; 100 (83.2, 100)     905.2 (649.0, 1262.6)   320.0, 2560.0                             

  M6              20             20; 100 (83.2, 100)     20; 100 (83.2, 100)     146.7 (100.4, 214.3)    40.0, 640.0                               

  M6+21           20             20; 100 (83.2, 100)     20; 100 (83.2, 100)     697.9 (502.6, 968.9)    160.0, 2560.0                             

  TIV-AS03~C~     day 0          20                      10; 50.0 (27.2, 72.8)   10; 50.0 (27.2, 72.8)   35.4 (13.6, 92.6)      \<10.0, 640.0      

  day 42          19             19; 100 (82.4, 100)     19; 100 (82.4, 100)     617.1 (251.0, 1516.8)   40.0, 5120.0                              

  M6              19             17; 89.5 (66.9, 98.7)   13; 68.4 (43.4, 87.4)   111.1 (47.3, 260.6)     \<10.0, 1280.0                            

  M6+21           19             19; 100 (82.4, 100)     19; 100 (82.4, 100)     921.8 (721.1, 1178.5)   453.0, 2560.0                             

  A/Uru/716/07\   TIV-AS03~D~    day 0                   20                      6; 30.0 (11.9, 54.3)    6; 30.0 (11.9, 54.3)   14.9 (6.6, 33.5)   \<10.0, 320.0
  (H3N2)                                                                                                                                           

  day 42          20             20; 100 (83.2, 100)     20; 100 (83.2, 100)     722.5 (473.8, 1101.7)   160.0, 3620.0                             

  M6              19             19; 100 (82.4, 100)     19; 100 (82.4, 100)     97.8 (57.8, 165.5)      40.0, 1280.0                              

  M6+21           20             20; 100 (83.2, 100)     20; 100 (83.2, 100)     607.6 (366.5, 1007.3)   80.0, 2560.0                              

  TIV-AS03~C~     day 0          20                      2; 10.0 (1.2, 31.7)     2; 10.0 (1.2, 31.7)     7.6 (4.1, 13.9)        \<10.0, 640.0      

  day 42          19             19; 100 (82.4, 100)     19; 100 (82.4, 100)     160.0 (86.3, 296.7)     40.0, 5120.0                              

  M6              19             14; 73.7 (48.8, 90.9)   5; 26.3 (9.1, 51.2)     21.5 (10.2, 45.4)       \<10.0, 1280.0                            

  M6+21           19             19; 100 (82.4, 100)     19; 100 (82.4, 100)     595.0 (375.2, 943.5)    80.0, 3620.0                              

  B/Bri/60/08     TIV-AS03~D~    day 0                   20                      1; 5.0 (0.1, 24.9)      1; 5.0 (0.1, 24.9)     5.9 (4.1, 8.5)     \<10.0, 160.0

  day 42          20             20; 100 (83.2, 100)     20; 100 (83.2, 100)     460.5 (320.4, 661.8)    113.0, 5120.0                             

  M6              20             20; 100 (83.2; 100)     18; 90.0 (68.3, 98.8)   60.6 (43.0, 85.5)       20.0, 640.0                               

  M6+21           20             20; 100 (83.2, 100)     20; 100 (83.2, 100)     273.9 (169.4, 442.9)    57.0, 1280.0                              

  TIV-AS03~C~     day 0          20                      1; 5.0 (0.1, 24.9)      1; 5.0 (0.1, 24.9)      5.9 (4.1, 8.5)         \<10.0, 160.0      

  day 42          19             19; 100 (82.4, 100)     14; 73.7 (48.8, 90.9)   63.1 (30.9, 128.8)      10.0, 5120.0                              

  M6              19             11; 57.9 (33.5, 79.7)   6; 31.6 (12.6, 56.6)    17.0 (8.7, 33.1)        \<10.0, 1280.0                            

  M6+21           19             19; 100 (82.4, 100)     19; 100 (82.4, 100)     325.9 (222.0, 478.3)    160.0, 1810.0                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

TIV, trivalent inactivated influenza vaccine; AS03, oil-in-water emulsion Adjuvant System containing 1.48 mg (AS03~D~) or 2.97 mg (AS03~C~) α-tocopherol

###### **Table 5.** Hemagglutination-inhibition assay based immunogenicity against the TIV booster strains at month 6 and month 6 + 21 d (according-to-protocol cohort): TIV-AS03~D~ (2 dose primary vaccination) and TIV-AS03~C~ (1 dose primary vaccination)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                       A(H1N1)pdm09    A/Victoria/210/2009 (H3N2)   B/Brisbane/60/2008                                                                                                                                   
  -------------------- --------------- ---------------------------- -------------------- ----------------- -------------- ---------------- ------------- ---------------- -------------- ---------------- -------------- ----------------
  **Titer ≥ 1:10%**\   100\            100\                         94.1\                100\              42.9\          100\             17.6\         100\             100\           100\             64.7\          100\
  **(95% CI)**         (76.8, 100)     (76.8, 100)                  (71.3, 99.9)         (80.5, 100)       (17.7, 71.1)   (76.8, 100)      (3.8, 43.4)   (80.5, 100)      (76.8, 100)    (76.8, 100)      (38.3, 85.8)   (80.5, 100)

  **GMT Value**\       160.0\          689.3\                       120.2\               869.0\            25.0\          353.3\           8.2\          226.2\           56.6\          262.5\           19.6\          294.9\
  **(95% CI)**         (99.9, 256.2)   (480.3, 989.2)               (51.5, 280.9)        (670.9, 1125.7)   (8.1, 77.4)    (215.8, 578.4)   (4.2, 15.7)   (143.6, 356.3)   (43.1, 74.3)   (152.6, 451.4)   (9.5, 40.2)    (203.7, 427.1)

  **SPR %**\           100\            100\                         70.6\                100\              42.9\          100\             11.8\         100\             92.9\          100\             35.3\          100\
  **(95% CI)**         (76.8, 100)     (76.8, 100)                  (44.0, 89.7)         (80.5, 100)       (17.7, 71.1)   (76.8, 100)      (1.5, 36.4)   (80.5, 100)      (66.1, 99.8)   (76.8, 100)      (14.2, 61.7)   (80.5, 100)

  **SCR %**\           \-              57.1\                        \-                   58.8\             \-             71.4\            \-            100\             \-             71.4\            \-             94.1\
  **(95% CI)**                         (28.9, 82.3)                                      (32.9, 81.6)                     (41.9, 91.6)                   (80.5, 100)                     (41.9, 91.6)                    (71.3, 99.9)

  **GMFR Value**\      \-              4.3\                         \-                   7.2\              \-             14.1\            \-            27.7\            \-             4.6\             \-             15.1\
  **(95% CI)**                         (2.6, 7.2)                                        (3.3, 16.0)                      (5.0, 40.0)                    (16.6, 46.5)                    (2.8, 7.8)                      (8.0, 28.4)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TIV, trivalent inactivated influenza vaccine; AS03, oil-in-water emulsion Adjuvant System containing 1.48 mg (AS03~D~) or 2.97 mg (AS03~C~) α-tocopherol; D, day; CI, confidence interval; GMT, geometric mean titer; SPR, seroprotection rate; SCR, seroconversion rate; GMFR, geometric fold rise; children received 2 doses of TIV-AS03~D~ or 1 dose of TIV-AS03~C~.

Incidence of fever by baseline serostatus
-----------------------------------------

All children who were seropositive for A(H1N1)pdm09 pre-vaccination developed post-vaccination fever (≥37.5 °C) after 1 dose of vaccine ([Fig. 3](#F3){ref-type="fig"}). After the first dose of vaccine in both vaccine groups, fever \>38 °C was more common in children who were seropositive for A(H1N1)pdm09 pre-vaccination than in those who were seronegative. Overall, 10/16 children who were seropositive for A(H1N1)pdm09 at baseline developed fever \>38 °C after the first vaccination, compared with 2/24 seronegative children. No relationship was observed for the incidence of fever and A/H3N2 or B-strain baseline serostatus ([Fig. 4](#F4){ref-type="fig"}).

![**Figure 3.** Maximum temperature during the 7-d post-vaccination period (dose 1) by baseline hemagglutination-inhibition antibody titers against A(H1N1)pdm09; *Footnote:*TIV, inactivated trivalent influenza vaccine; HI, hemagglutination inhibition ; AS03, oil-in-water emulsion Adjuvant; System containing 1.48 mg (AS03~D~) or 2.97 mg (AS03~C~) α-tocopherol ; Children with titers of ≥ 10 were considered to be seropositive.](hvi-10-1959-g3){#F3}

![**Figure 4.** Maximum temperature during the 7-d post-vaccination period (dose 1) by baseline hemagglutination-inhibition antibody titers against influenza B (**A**) and A/H3N2 (**B**); *Footnote:*AS03, oil-in-water emulsion Adjuvant System containing 1.48 mg (AS03~D~) or 2.97 mg (AS03~C~) α-tocopherol ; Children with titers of ≥10 were considered to be seropositive.](hvi-10-1959-g4){#F4}

Discussion
==========

This phase 1, open-label study assessed the reactogenicity, safety, and immunogenicity, of a seasonal TIV containing a low dose of antigen, and adjuvanted with AS03~D~ (1.48 mg tocopherol) or AS03~C~ (2.97 mg tocopherol) in influenza vaccine-naïve children aged 6 to 35 mo. At 21 d after 2 doses of TIV-AS03~D~, the seroconversion rate was 100% against each vaccine strain. TIV-AS03~C~ was also highly immunogenic, but the incidence of fever \>38.0 °C during 3 d after the first dose was 35.0% (7/20) which fulfilled the pre-defined holding-rule for safety; the GlaxoSmithKline Vaccine Safety Monitoring Board cancelled the second dose of TIV-AS03~C~ and the sequential enrolment of children to receive TIV-AS03~B~ (5.93 mg tocopherol).

In view of the considerable burden of influenza infection and the relatively poor antibody responses to trivalent influenza vaccines in children aged \<2 y, there is a need for seasonal influenza vaccines with improved immunogenicity profiles for use in unprimed infants. The formulation of TIVs with an oil-in-water adjuvant was recently shown to be a feasible strategy for enhancing immunogenicity, and improving efficacy of seasonal influenza vaccine in young children; the large, randomized field study showed that TIV formulated with MF59 provided better efficacy against PCR-confirmed influenza than conventional TIV when given as a 2 dose schedule over consecutive seasons.[@R7] In addition, the use of adjuvanted TIV for out of season priming, followed by a booster dose of conventional TIV is a possible vaccination strategy for very young children. For example, in a study of previously unprimed children aged 15 to 20 mo, 1 dose of TIV containing the A(H1N1)pdm09 strain elicited antibody responses of ≥1:40 against A(H1N1)pdm09 in children who had received monovalent AS03-adjuvanted A(H1N1)pdm09 vaccine 1 yr before, but 2 doses of TIV were needed to provide adequate immune responses to the A/H3N2 and B-strains.[@R14]

In our study, 21 d after 2 doses of TIV-AS03~D~ or 42 d after 1 dose of TIV-AS03~C~, HI SPRs, SCRs, and GMFRs exceeded adult EU licensure criteria for the immunogenicity of influenza vaccine against all vaccine strains, and apart from the B-strain in the TIV-AS03~C~ group, the SPRs and SCRs were 100%. At 6 mo, SPRs against primary vaccine strains were 100% for A(H1N1)pdm09 and A/H3N2 (A/Uruguay) and 90.0% against the B-strain in the TIV-AS03~D~ group (2 doses), and 68.4%, 26.3%, and 31.6% against A(H1N1)pdm09, A/H3N2 (A/Uruguay), and the B-strain, respectively in the TIV-AS03~C~ group (1 dose). Despite the differences in persistence against the primary vaccination strains at 6 mo, the booster dose of TIV induced HI SPRs of 100% against all booster vaccine strains in both primary vaccine groups. Furthermore, the A/H3N2 strain in the TIV booster (A/Victoria) was a different strain to that in the primary vaccines (A/Uruguay), suggesting that heterologous priming is feasible even with 1 dose of AS03-adjuvanted priming vaccine. Although based on a small number of children, our results show that 1 dose of TIV-AS03~C~ followed by a 6-mo homologous or heterologous booster dose of TIV is a possible strategy for influenza vaccine-naïve children.

AS03-adjuvanted pandemic influenza vaccines are reported to be more reactogenic than non-adjuvanted vaccines, although increased reactogenicity is considered acceptable in a pandemic setting.[@R6]^,^[@R9]^,^[@R12]^,^[@R15] Notably, previous studies in children show that AS03~B~-adjuvanted A(H1N1)pdm09 vaccine vs. non-adjuvanted A(H1N1)pdm09 vaccine is associated with higher rates of injection site pain and general symptoms such as irritability and loss of appetite.[@R9] In our study, we assessed vaccine formulated with AS03~C~ and AS03~D~ to evaluate whether reducing the dosage of adjuvant could improve the tolerability profile of the vaccine. We showed that the most frequent solicited injection site event was pain, which was mostly mild in intensity. Injection site pain was reported by 30.0% of children in both vaccine groups after the first dose and by 35.0% of children after the second dose of TIV-AS03~D~. Consistent with the known reactogenicity profile of AS03-adjuvanted pandemic vaccines in younger children, the most frequent solicited general events in the TIV-AS03~D~ group during each 7-d post vaccination period were fever (≥37.5 °C), loss of appetite, and vomiting. The incidence of fever \>38 °C increased from 25.0% to 35.0% after the first and second doses of TIV-AS03~D~, respectively, and there were 7 reports (35.0%) of fever \>38 °C after TIV-AS03~C~, which resulted in the cancellation of the second dose of TIV-AS03~C~.

An exploratory analysis of fever after 1 dose of each vaccine according to baseline serostatus for the vaccine strains was conducted. Although very few children overall were seropositive for the A/H3N2 strain and the B-strain pre-vaccination (8 and 2 children, respectively), 16 children were seropositive for the A(H1N1)pdm09 strain. The analysis showed that after 1 dose of vaccine, 10/16 children who were seropositive for the A(H1N1)pdm09 strain pre-vaccination developed fever \>38 °C, compared with 2/24 seronegative children. Since the study was conducted out of the classical influenza season period as from April 2010 just after the pandemic period, recent exposure of children to the A(H1N1)pdm09 strain was likely to be high. The subjects who were primed with natural pandemic influenza strain showed relatively high rates of fever after the first dose of the candidate vaccine formulation. Similar observations were made in previous studies post-dose 2 in pandemic influenza naive children.[@R16]^-^[@R19] The higher fever rates observed might have been associated with a stronger increase of the humoral response after dose 1 in already primed children. However this would require further investigation as the number of vaccinees is low and the study design limited the blood sampling to the post dose 2 time point.

However, the rate of fever \>38 °C after the TIV booster dose was n = 1 (5.0%) and n = 3 (15.8%) in children who were primed with TIV-AS03~D~ or TIV-AS03~C~, respectively, suggesting that although fever was increased during the primary vaccinations, this did not impact reactogenicity following booster doses of classical TIV. No SAEs were considered vaccine related and no febrile convulsion occurred in the days following vaccination.

In summary, this study showed that a TIV containing a low dose of antigen and adjuvanted with a low dose of AS03 (AS03~D~ or AS03~C~) induced strong immune responses to the vaccine strains in unprimed children aged 6 to 35 mo, which persisted at 6 mo post-vaccination. The use of 1 single dose of a conventional TIV at 6 mo post-priming provided 100% seroprotection (antibody titer ≥ 1:40) in all children for each booster strain after 2-dose priming with AS03~D~ and single dose priming with AS03~C~. There was a relatively high frequency of fever, yet apart from fever, the tolerability and safety profile of TIV-AS03~D~ and TIV-AS03~C~ was consistent with that previously reported with AS03-adjuvanted pandemic vaccine in very young children. The generalizability of the findings however is uncertain given that the study was not controlled and the vaccine was administered "out of season". Pre-screening was not done so as to reduce the number of blood draws and since it would not have ruled out any intercurrent infection. Therefore many of the children had antibody evidence suggesting recent infection with A(H1N1)pdm09. Based on these pilot data, a more complete dose range study in which both antigen and AS03 dose are varied would be needed to confirm that indeed 1 dose of primary vaccine containing a low dose of antigen and AS03 may be a possible influenza vaccination strategy for young children.

Methods
=======

Participants
------------

This phase 1, open-label study assessed the reactogenicity, safety, and immunogenicity of 2 doses of AS03-adjuvanted TIV followed by a 6-mo booster dose of non-adjuvanted TIV in children aged between 6 and 35 mo. The study was conducted at the Instituto Hispalense de Pediatría, Seville, Spain.

Eligible children were healthy, were influenza vaccine-naïve, and had received other appropriate scheduled childhood vaccination administered 30 d before or 30 d after the study vaccine. Parents/guardians were deemed to be able to comply with the protocol and provided informed written consent. The exclusion criteria list included the receipt of any seasonal or pandemic influenza vaccine before or during the study, or any investigational vaccine within the preceding 30 d or during the study.

The study protocol was approved by Independent Ethics Committees or local or central Institutional Review Boards, and was conducted in accordance with Good Clinical Practice, the principles of the Declaration of Helsinki, and all regulatory requirements. ClinicalTrials.gov, number NCT01096056.

Vaccines and design
-------------------

Children were scheduled to receive TIV containing 7.5 μg HA of each strain based on the World Health Organisation's (WHO) recommended A/H3N2 and B-strain, plus the A(H1N1)pdm09 strain: A(H1N1)pdm09, A/Uruguay/7/16/2007 (H3N2), and B/Brisbane/60/2008 (B-strain; Victoria lineage). The vaccine was adjuvanted with an oil-in-water emulsion based Adjuvant System containing the following differing amounts of α-tocopherol and squalene, respectively: 1.48 mg and 1.337 mg (AS03~D~), 2.97 mg and 2.675 mg (AS03~C~), and 5.93 mg, and 5.35 mg (AS03~B~). The TIV and the Adjuvant System were manufactured by GlaxoSmithKline Vaccines.

Three sequential phases comprising TIV-AS03~D~, TIV-AS03~C~, and TIV-AS03~B~ were planned, each including 20 children scheduled to receive 1 dose of vaccine in the first instance; the administration of a second dose 21 d after the first, and the sequential enrollment of the next vaccine with the higher dose of AS03 was conditional on the outcome of an internal safety assessment based on pre-defined holding rules. A review of reactogenicity data was performed for 3 d after the first dose of TIV-AS03~D~ and the study proceeded to day 21; children received a second dose of TIV-AS03~D~ and the next sequential group received the first dose of TIV-AS03~C~. The incidence of fever during the 3-d post-vaccination period for TIV-AS03~C~ fulfilled the pre-defined holding-rule and, therefore, no further dosing of the investigational vaccine was performed in the study (i.e., the second dose of TIV-AS03~C~ and TIV-AS03~B~ were not administered).

The 6-mo booster vaccine was TIV (*Fluarix™;* GlaxoSmithKline Vaccines) containing 15 μg HA of each strain: A(H1N1)pdm09 strain, A/Victoria/210/2009 (H3N2), and B/Brisbane/60/2008 (B strain; Victoria lineage), i.e., homologous booster for A(H1N1)pdm09 strain and B-strain, heterologous for A/H3N2 strain. Vaccines were administered intramuscularly into the anterolateral region of the thigh in children aged \<12 mo and in the deltoid of children aged ≥12 mo.

Endpoints
---------

The primary endpoint was the incidence of axillary temperature \>38 °C during the 7-d post-vaccination period following each dose of adjuvanted vaccine. Secondary objectives were to assess the incidence of solicited AEs during the 7-d post-vaccination periods and unsolicited AEs during the 21-d post-vaccination periods after adjuvanted vaccine. MAEs, SAEs, and pIMDs were assessed from the day of vaccination (day 0) until 21 d after the TIV booster vaccination (month 6 + 21 d).

Secondary immunogenicity endpoints were HI assay-based antibody titers against the vaccine strains pre-vaccination (day 0) and at day 42 (21 d after the second dose of TIV-AS03~D~ and 42 d after the first dose of TIV-AS03~C~).

Further assessments included: immunogenicity before the TIV booster vaccination at month 6 and 21 d after the TIV booster against the strains in the primary vaccine (primary vaccine strains) and booster vaccine strains; and the incidence of post-vaccination fever according to baseline seropositivity status for each primary vaccine strain.

Reactogenicity and safety
-------------------------

Solicited injection site and general AEs were assessed on the day of each vaccination and for 6 subsequent days (7-d follow-up). Solicited symptoms were recorded by parents/guardians and graded for intensity using diary cards. Solicited injection site events were pain (Grade 1 pain was defined as a minor reaction on touch; Grade 2 as cries on touch and Grade 3 as cries when limb is moved/spontaneously painful), redness, and swelling; general solicited events were drowsiness, fever, irritability/fussiness, appetite loss, and vomiting. Fever was defined as an axillary temperature: ≥37.5 °C; \>38.0 °C; \>39.0 °C; \>40.0 °C. Temperature was recorded in the evening.

Unsolicited AEs, MAEs, SAEs and pIMDs were classified by MedDRA Preferred Terms. All injection site reactions were considered to be vaccine-related and investigators judged the relationship between vaccination and solicited general symptoms and unsolicited symptoms.

Immunogenicity
--------------

Blood was collected on day 0, day 42, month 6, and month 6 + 21 d for serological testing. Antibody titers against the vaccine strains were assessed using validated micro-titer HI assay as previously described.[@R20]

HI antibody responses were described as the anti-log of the arithmetic mean of the log-10 transformed titers (GMTs), SCR, SPR, and GMFR. Children with titers of ≥1:10 were considered to be seropositive.

Analyses
--------

A sample size of 20 children per group was based on the assumption that an incidence of fever \>38.0 °C of 20% may be within clinical acceptance whereas an incidence of \>50% raises clinical concern. Based on a sample of 20 children, an incidence of fever \>38.0 °C of ≥35.0% was identified in the protocol as a holding rule for the study.

The incidences of solicited and unsolicited AEs, MAEs, and SAEs were calculated with a 2-sided 95% CI. Immunogenicity endpoints were provided with a 2-sided 95% CI. The HI antibody titers were assessed according to the European All Committee for Medicinal Products for Human Use (CHMP) recommendations for influenza vaccines in adults.[@R21] The licensure criteria are fulfilled if the point estimate for SPR is \>70%, SCR \>40%, and GMFR \>2.5.

Reactogenicity, safety, and immunogenicity at day 0 and day 42 were assessed in the total vaccinated cohort, including all children who received at least 1 dose of AS03 vaccine. Immunogenicity analyses at month 6 and month 6 + 21 d were performed on the according-to-protocol (ATP) cohort including vaccinated children without protocol violation and who complied with the vaccination and serological testing schedule.
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